Andriole

Bozeman

Brawer

Brown

Debruyne

Espana

Fenter

Finasteride Study Group

Fowke

Guess

Holtgrewe

Hong

Iehle

In Rae Cho

Issa

Marihart

McConnell

Milam

Naslund

O'Leary

Potts

Roehrborn

Span

Sung Yong Cho

Thorpe

Titus

Yong Hyeuk Choi

English

PubMed

Crossref

The Different Reduction Rate of Prostate-Specific Antigen in Dutasteride and Finasteride

A large retrospective analysis of acute urinary retention and prostate-related surgery in BPH patients treated with 5-alpha reductase inhibitors: dutasteride versus finasteride.

A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.

Association of nonsteroidal anti-inflammatory drugs, prostate specific antigen and prostate volume.

Benign prostatic hyperplasia. Lancet

Changes in molecular forms of prostate-specific antigen during treatment with finasteride.

Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride.

Dutasteride vs finasteride: assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged ＞ or =65 years.

Dutasteride: a review of current data on a novel dual inhibitor of 5alpha reductase.

Effect of dutasteride on the risk of prostate cancer.

Effect of finasteride and/or terazosin on serum PSA: results of VA Cooperative Study #359. Prostate

Effect of finasteride on serum PSA concentration in men with benign prostatic hyperplasia. Results from the North American phase III clinical trial. Urol Clin North Am

Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer.

Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Finasteride Study Group. Prostate 1993;22:291-9. 7 . D e b r u y n e F , B a r k i n J , v a n E r p s P ,

Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia.

Hong SJ. Changes in prostate volume, transitional zone volume and PSA after cessation of the finasteride.

Human prostatic steroid 5 alpha-reductase isoforms--a comparative study of selective inhibitors.

Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor.

Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies.

Prospective identification of National Institutes of Health category Category IV prostatitis in men with elevated prostate specific antigen.

Selectivity of finasteride as an in vivo inhibitor of 5 alpha-reductase isozyme enzymatic activity in the human prostate.

Serial prostate-specific antigen measurements in patients with clinical benign prostatic hyperplasia enrolled in a randomized,

Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer.

Terazosin and finasteride both lower the serum prostate-specific antigen (PSA) level in men with benign prostatic hyperplasia (BPH).

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.

Transurethral prostatectomy: practice aspects of the dominant operation in American urology.

Treatment of chronic prostatitis lowers serum prostate specific antigen.

http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2963784

The Different Reduction Rate of Prostate-Specific Antigen in Dutasteride and Finasteride

Abstract

Similar works

Full text

Available Versions

Crossref